留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

林奇综合征相关子宫内膜癌研究进展

刘晓 李玉兰 马杏 许飞雪

刘晓, 李玉兰, 马杏, 许飞雪. 林奇综合征相关子宫内膜癌研究进展[J]. 协和医学杂志, 2023, 14(1): 190-195. doi: 10.12290/xhyxzz.2022-0189
引用本文: 刘晓, 李玉兰, 马杏, 许飞雪. 林奇综合征相关子宫内膜癌研究进展[J]. 协和医学杂志, 2023, 14(1): 190-195. doi: 10.12290/xhyxzz.2022-0189
LIU Xiao, LI Yulan, MA Xing, XU Feixue. Advances in the Study of Lynch Syndrome Associated Endometrial Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 190-195. doi: 10.12290/xhyxzz.2022-0189
Citation: LIU Xiao, LI Yulan, MA Xing, XU Feixue. Advances in the Study of Lynch Syndrome Associated Endometrial Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 190-195. doi: 10.12290/xhyxzz.2022-0189

林奇综合征相关子宫内膜癌研究进展

doi: 10.12290/xhyxzz.2022-0189
基金项目: 

甘肃省科技计划 21JR7RA378

详细信息
    通讯作者:

    许飞雪, E-mail: xfx.sxq@163.com

  • 中图分类号: R711; R737.3

Advances in the Study of Lynch Syndrome Associated Endometrial Cancer

Funds: 

Science and Technology Project of Gansu Province 21JR7RA378

More Information
  • 摘要: 林奇综合征(Lynch syndrome, LS)是错配修复基因缺陷引起的常染色体显性遗传病,多系统恶性肿瘤易感是其主要特征,LS相关子宫内膜癌(LS associated endometrial cancer,LS-EC)是LS最常见的肠外前哨癌。精准医学时代,LS-EC的早期筛查对于预防LS相关其他恶性肿瘤的发生具有重要意义。本文就LS-EC的筛查手段及预防研究进展进行综述,以期为LS相关肿瘤患者精准诊疗及预防提供参考。
    作者贡献:刘晓负责检索文献、框架设计和论文初稿撰写;李玉兰负责修订论文初稿;马杏负责指导论文写作及终稿审核。
    利益冲突:所有作者均声明不存在利益冲突
  • 图  1  LS-EC患者筛查流程建议[2]

    MMR:错配修复基因;LS:林奇综合征;MSI:微卫星不稳定;EC:子宫内膜癌;LS-EC:林奇综合征相关子宫内膜癌

  • [1] Dörk T, Hillemanns P, Tempfer C, et al. Genetic Susceptibility to Endometrial Cancer: Risk Factors and Clinical Management[J]. Cancers (Basel), 2020, 12: 2407. doi:  10.3390/cancers12092407
    [2] Zhao S, Chen L, Zang Y, et al. Endometrial cancer in Lynch syndrome[J]. Int J Cancer, 2022, 150: 7-17. doi:  10.1002/ijc.33763
    [3] Pastor DM, Schlom J. Immunology of Lynch Syndrome[J]. Curr Oncol Rep, 2021, 23: 96. doi:  10.1007/s11912-021-01085-z
    [4] Poulogiannis G, Frayling IM, Arends MJ. DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome[J]. Histopathology, 2010, 56: 167-179. doi:  10.1111/j.1365-2559.2009.03392.x
    [5] Kempers MJ, Kuiper RP, Ockeloen CW, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study[J]. Lancet Oncol, 2011, 12: 49-55. doi:  10.1016/S1470-2045(10)70265-5
    [6] Morak M, Ibisler A, Keller G, et al. Comprehensive analysis of the MLH1 promoter region in 480 patients with colorectal cancer and 1150 controls reveals new variants including one with a heritable constitutional MLH1 epimutation[J]. J Med Genet, 2018, 55: 240-248. doi:  10.1136/jmedgenet-2017-104744
    [7] Dominguez-Valentin M, Sampson JR, Seppälä TT, et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database[J]. Genet Med, 2020, 22: 15-25. doi:  10.1038/s41436-019-0596-9
    [8] Ryan NAJ, Morris J, Green K, et al. Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome: Implications for Stratified Surveillance Strategies[J]. JAMA Oncol, 2017, 3: 1702-1706. doi:  10.1001/jamaoncol.2017.0619
    [9] Staff S, Aaltonen M, Huhtala H, et al. Endometrial cancer risk factors among Lynch syndrome women: a retrospective cohort study[J]. Br J Cancer, 2016, 115: 375-381. doi:  10.1038/bjc.2016.193
    [10] Broaddus RR, Lynch HT, Chen LM, et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma[J]. Cancer, 2006, 106: 87-94. doi:  10.1002/cncr.21560
    [11] Rossi L, Le Frere-Belda MA, Laurent-Puig P, et al. Clinicopathologic Characteristics of Endometrial Cancer in Lynch Syndrome: A French Multicenter Study[J]. Int J Gynecol Cancer, 2017, 27: 953-960. doi:  10.1097/IGC.0000000000000985
    [12] Ramchander NC, Ryan NAJ, Walker TDJ, et al. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer[J]. Front Immunol, 2020, 10: 3023. doi:  10.3389/fimmu.2019.03023
    [13] Bogani G, Tibiletti MG, Ricci MT, et al. Lynch syndrome-related non-endometrioid endometrial cancer: analysis of outcomes[J]. Int J Gynecol Cancer, 2020, 30: 56-61. doi:  10.1136/ijgc-2019-000824
    [14] Carr C, Son J, Yao M, et al. Clinicopathologic characteri-stics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening[J]. Gynecol Oncol, 2020, 159: 712-720. doi:  10.1016/j.ygyno.2020.09.039
    [15] 杨子慧, 刘新宇, 杨曦, 等. 林奇综合征患者子宫内膜癌及卵巢癌的筛查与预防[J]. 国际妇产科学杂志, 2021, 48: 453-456. Yang ZH, Liu XY, Yang X, et al. Screening and prevention of endometrial carcinoma and ovarian cancer in patients with Lynch syndrome[J]. Guoji Fuchanke Zazhi, 2021, 48: 453-456. doi:  10.12280/gjfckx.20201174
    [16] Raevaara TE, Korhonen MK, Lohi H, et al. Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1[J]. Gastroenterology, 2005, 129: 537-549.
    [17] Leclerc J, Vermaut C, Buisine MP. Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors[J]. Cancers (Basel), 2021, 13: 467. doi:  10.3390/cancers13030467
    [18] Dietmaier W, Wallinger S, Bocker T, et al. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression[J]. Cancer Res, 1997, 57: 4749-4756.
    [19] Houlleberghs H, Dekker M, Lusseveld J, et al. Three-step site-directed mutagenesis screen identifies pathogenic MLH1 variants associated with Lynch syndrome[J]. J Med Genet, 2020, 57: 308-315. doi:  10.1136/jmedgenet-2019-106520
    [20] Gallon R, Gawthorpe P, Phelps RL, et al. How Should We Test for Lynch Syndrome? A Review of Current Guidelines and Future Strategies[J]. Cancers (Basel), 2021, 13: 406. doi:  10.3390/cancers13030406
    [21] Lu KH, Broaddus RR. Endometrial Cancer[J]. N Engl J Med, 2020, 383: 2053-2064. doi:  10.1056/NEJMra1514010
    [22] Van den Heerik ASVM, Horeweg N, De Boer SM, et al. Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy[J]. Int J Gynecol Cancer, 2021, 31: 594-604. doi:  10.1136/ijgc-2020-001822
    [23] Gompel A. Progesterone and endometrial cancer[J]. Best Pract Res Clin Obstet Gynaecol, 2020, 69: 95-107. doi:  10.1016/j.bpobgyn.2020.05.003
    [24] Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency[J]. N Engl J Med, 2015, 372: 2509-2520. doi:  10.1056/NEJMoa1500596
    [25] Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsa-tellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase Ⅱ KEYNOTE-158 Study[J]. J Clin Oncol, 2020, 38: 1-10.
    [26] Burn J, Sheth H, Elliott F, et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial[J]. Lancet, 2020, 395: 1855-1863. doi:  10.1016/S0140-6736(20)30366-4
    [27] Seppälä TT, Dominguez-Valentin M, Crosbie EJ, et al. Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospec-tive Lynch Syndrome Database report[J]. Eur J Cancer, 2021, 148: 124-133. doi:  10.1016/j.ejca.2021.02.022
    [28] Crosbie EJ, Ryan NAJ, Arends MJ, et al. Manchester International Consensus Group, Evans DG. The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome[J]. Genet Med, 2019, 21: 2390-2400. doi:  10.1038/s41436-019-0489-y
    [29] Roudko V, Cimen Bozkus C, Greenbaum B, et al. Lynch Syndrome and MSI-H Cancers: From Mechanisms to "Off-The-Shelf" Cancer Vaccines[J]. Front Immunol, 2021, 12: 757804. doi:  10.3389/fimmu.2021.757804
    [30] Bayó C, Jung G, Español-Rego M, et al. Vaccines for Non-Viral Cancer Prevention[J]. Int J Mol Sci, 2021, 22: 10900. doi:  10.3390/ijms222010900
  • 加载中
图(1)
计量
  • 文章访问数:  164
  • HTML全文浏览量:  34
  • PDF下载量:  45
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-04-07
  • 录用日期:  2022-04-15
  • 网络出版日期:  2022-05-31
  • 刊出日期:  2023-01-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!